Drug Resistance and Sensitivity Network (DRSN)
Drug Resistance and
Sensitivity Network
Toggle Menu
Drug Resistance and
Sensitivity Network
About
Featured Talk
Background
Organization
White Paper
Members
DRSN Research Centers
DRSN Supplement Projects
DRSN Revision Projects
DRSN Coordination Center
Working Groups
DRSN Working Groups
Organoid Bulletin Board
Funding
ARTNet (next phase of DRSN)
DRSN Administrative Supplement
DRSN Revision Application
Events
DRSN Event Calendar
Upcoming Webinars
Cancer Moonshotâ„ Seminar Series
Computational Immuno-oncology Webinars
Workshop on Immunomodulatory Agents
Past Events
Publications
DRSN Reviews
Resources
All Resources
Policy
Data
Model
Software
Clinical Trial
Education
DRSN Awardees
U54 DRSN Research Centers
U54CA224019
U54CA224019 Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML
Oregon Health & Science University
Center Overview
Supplement Application
Tyner, Jeffrey
Druker, Brian
Agarwal, Anupriya
U54CA224079
The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity Center
Memorial Sloan Kettering Cancer Center
Center Overview
Supplement Application
Sawyers, Charles
Chen, Yu
Carver, Brett
5U54CA224081
Bay Area Team Against Resistance
University of California, San Francisco
Stanford University
Center Overview
Supplement Application
Bivona, Trever
Kuo, Calvin
U54CA224068
An Integrated Translational Approach to Overcome Drug Resistance
Massachusetts General Hospital
Center Overview
Supplement Application
Corcoran, Ryan
Flaherty, Keith
U54CA224018
Overcoming Drug Resistance In Multiple Myeloma
Mayo Clinic/University of Minnesota
Center Overview
Supplement Application
Bergsagel, Leif
Kumar, Shaji
Meurice, Nathalie
Stewart, Keith
Van Ness, Brian
DRSN Supplement Projects
3U01CA217885-03S1
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic States
University of California San Diego
Kaufman, Dan
Tyner, Jeffrey (
DRSN U54
)
4U54CA224065-02
University of Texas PDX Development and Trial Center
MD Anderson Cancer Center
Roth, Jack
Bivona, Trever (
DRSN U54
)
3R01CA192844-04S1
The Role of CD86 In Multiple Myeloma
Winship Cancer Institute of Emory University
Boise, Lawrence
Stewart, Keith (
DRSN U54
)
3R01CA207757-03S1
Exploiting RB1 Deficiency for the Treatment of Lethal Neuroendocrine Prostate Cancer
Roswell Park Comprehensive Cancer Center
Goodrich, David
Stewart, Keith (
DRSN U54
)
3R01CA131261-09S2
Studying the Initiation, Progression and Therapy of Lung Cancer in Mouse Models
Huntsman Cancer Institute - University of Utah Health
Mcmahon, Martin
Bivona, Trever (
DRSN U54
)
3R37CA230617-02S1
Hormone Signaling and Translation Control in Advanced Prostate Cancer
Fred Hutchinson Cancer Research Center
Hsieh, Andrew
Sawyers, Charles (
DRSN U54
)
3R01CA251858-01A1S1
Dissecting Single-cell Response or Resistance to Novel Combination Therapy in AML using Mass Cytometry
Stanford University
Davis, Kara Lynn
Tyner, Jeffrey (
DRSN U54
)
Druker, Brian (
DRSN U54
)
3U01CA225730-03S1
Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis
Dana-Farber Cancer Institute
Mitisades, Constantine
Sackstein, Robert
DRSN Revision Projects
3U01CA223976-03S1
Glioblastoma Tumor Microenvironmental Influence on Acquired and Inherent Cancer Therapy Resistance
University of Alabama at Birmingham
Willey, Christopher
Gillespie, Yancey
Hjelmeland, Anita
3P50CA186786-07S1
Targeting LSD1 in Neuroendocrine Prostate Cancer - Michigan Prostate SPORE
University of Michigan at Ann Arbor
Chinnaiyan, Arul
Alumkal, Joshi
3U01CA231776-03S1
Tumor-barcoding coupled with high-throughput sequencing of a novel chemoradiation resistant SCLC mouse model
Johns Hopkins University
Tran, Phuoc T
3R01CA175397-07S1
A vicious cycle of pyroptotic cancer cells and fibroblasts fuels chemoresistance
Cedars Sinai Medical Center
Chan, Keith Syson
3R01CA231011-03S1
Long Noncoding RNA Advocates Immune Resistant Microenvironment
MD Anderson Cancer Center
Lin, Chunru
5R01CA254354-02
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia
Versiti
Deininger, Michael
5R01CA247362-03
RB tumor suppressor as a therapeutic target in ER-positive breast cancer
Roswell Park Comprehensive Cancer Center
Knudsen, Eric
Witkiewicz, Agnieszka
5R01CA248310-02
Development of a first-in-class mEGFR dimerization inhibitor
University of Michigan at Ann Arbor
Nyati, Mukesh
5R01CA244729-02
The Evolution of Sarcoma Drug Sensitivity through Time and Space
University of California Los Angeles
Soragni, Alice
Boutros, Paul
5R01CA251872-02
Drivers of metabolic plasticity promote radiation resistance in glioblastoma multiforme
University of California Los Angeles
Vlashi, Erina
5R01CA175495-09
The B7x pathways in the tumor microenvironment
Albert Einsten College of Medicine
Zang, Xingxing
DRSN Coordination Center
U24CA232979
Drug Resistance and Sensitivity Network: Coordination Center
Roswell Park Comprehensive Cancer Center
Hutson, Alan
Liu, Song
Morgan, Martin
Odunsi, Kunle